GlobeNewswire·Nov 10, 2026, 4:05 PM ET

Bionano Reports Third Quarter 2026 Results and Provides a Business Update

Bionano Genomics reported Q3 2026 total revenue of $8.3 million, a 12% increase from $7.4 million in Q3 2025.
Consumables revenue reached $4.7 million in Q3 2026, representing a 24% year-over-year increase.
The company sold 9,870 flowcells in Q3 2026, an 18% rise compared to 8,390 units sold in the prior year period.
Gross margin for Q3 2026 was 48%, up from 46% in Q3 2025.
Operating expenses decreased 12% to $10.5 million, while adjusted operating expenses fell 9% to $8.8 million.
Bionano reiterated its full-year 2026 revenue guidance range of $31 million to $33 million.
Recent milestones include state-level approvals for OGM tests, new peer-reviewed publications on clinical value, and increased adoption at academic cancer centers.
The company's cash and cash equivalents stood at $4,355,000 as of September 30, 2026.
The company reported a net loss of $6.45 million for the three months ended September 30, 2026.
A conference call to discuss these results was held on November 10, 2026, at 4:30 PM ET.